Disuccinimidyl glutarate

Disuccinimidyl glutarate (DSG) is a widely used ADC linker reagent in the construction of antibody-drug conjugates (ADCs) and targeted bioconjugation studies. As a homobifunctional N-hydroxysuccinimide (NHS) ester linker, DSG enables stable and efficient conjugation between monoclonal antibodies and ADC cytotoxins through primary amine groups. Its five-carbon glutarate spacer provides flexibility and optimal linker length, allowing modular ADC linker design that preserves antibody structure and maintains antigen-binding specificity. In ADC linker applications, DSG supports predictable and reproducible payload attachment, enhancing pharmacokinetic properties and intracellular delivery of ADC payloads.

DSG is compatible with a variety of ADC cytotoxins, including microtubule inhibitors, DNA-targeting agents, and other potent payloads. Its bifunctional NHS ester groups allow rapid and site-specific conjugation under mild aqueous conditions, reducing aggregation and maintaining antibody functionality. The glutarate spacer provides chemical flexibility, facilitating optimal intracellular release of ADC payloads while maintaining systemic stability. Researchers can employ DSG to construct homogeneous and high-performance ADCs, supporting both preclinical research and scalable industrial production of therapeutic conjugates.

From an application perspective, Disuccinimidyl glutarate is extensively used in oncology-focused ADC research, protein bioconjugation studies, and targeted drug delivery systems. Its predictable reactivity, spacer flexibility, and compatibility with diverse ADC cytotoxins make it suitable for constructing cleavable or non-cleavable linker strategies. By integrating DSG into ADC linker design, developers can achieve stable, flexible, and efficient conjugation, supporting optimized tumor-specific delivery, enhanced pharmacokinetics, and improved therapeutic outcomes in modern ADC development.